环丝氨酸用后多久见效？

(cycloserine) has an inhibitory effect on Mycobacterium tuberculosis, and its anti-Mycobacterium tuberculosis effect is far weaker than that of isoniazid and streptomycin. Its antibacterial mechanism is to interfere with the synthesis of bacterial cell walls. The concentration of anti-Mycobacterium tuberculosis is 5 to 20 mg/L. It has no cross-resistance with other anti-tuberculosis drugs, and bacteria are not easy to develop resistance to it. Today we will learn more about how long it takes for cycloserine to take effect after use?

Clinical experiments have proven that the combination of cycloserine, isoniazid and rifampicin can improve patient survival rates. The efficacy of second-line drugs is relatively weak, and the treatment time is usually more than 2 years. Of 2033 sputum specimens (6099) in India reviewed from 1991 to 1995, 521 (25.6%) patients (335 males and 186 females; aged 11 to 75 years) had positive sputum cultures and sensitive acid-fast bacilli (AFB) reactions.

The relevant resistance patterns studied were: isoniazid 15%, rifampicin 66.8%, pyrazinamide 72.2%, ethambutol 8.4%, streptomycin 53.6%, cycloserine 39.2%, streptomycin 25.1% and ethionamide 65.3%. In 1998, India's Tuberculosis Research Department reported that the resistance to isoniazid, rifampicin and streptomycin in more than 200 patients was 72%, 49% and 37% respectively, while the resistance to cycloserine and ethionamide was only 1%.

From May 2014 to April 2015, 48 patients with MDR-TB (Multi-drug-resistant tuberculosis) diagnosed in the tuberculosis prevention clinic and treated by the Global Fund's multi-drug-resistant tuberculosis prevention and treatment project were selected as research subjects. They were randomly divided into an experimental group (n=24) and a control group (n=24). Both groups of patients received the WHO standard MDR-TB treatment plan. The experimental group added cycloserine (cycloserine) on this basis. The efficacy and adverse drug reactions of the two groups of patients at different treatment periods were observed.

The results at the end of 24 months of treatment showed that the sputum bacterial negative conversion rates in the experimental group and the observation group were 87.5% and 62.5% respectively, and the lesion absorption improvement rates were 87.5% and 62.5% respectively. The difference between the two groups was statistically significant; the incidence rate of central nervous system disease in the experimental group was higher than that in the observation group, and the incidence rate of drug-induced liver injury in the observation group was higher than that in the experimental group, and the difference was statistically significant. Combining cycloserine with other anti-tuberculosis drugs in the treatment of multi-drug-resistant pulmonary tuberculosis can speed up the conversion of acid-fast staining of sputum tuberculosis bacteria to negative, promote the absorption of lesions, and has no serious adverse reactions. It is safe and well-tolerated and is worthy of promotion.

The above is the content of the treatment effect, I hope it can help you!

Recommended related hot articles: /newsDetail/83333.html